Endologix Inc. (NASDAQ:ELGX)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer Holdings Inc. in a report issued on Tuesday. They currently have a $15.00 price objective on the stock. Oppenheimer Holdings Inc.’s price target points to a potential upside of 17.83% from the stock’s current price.
Other analysts have also issued research reports about the stock. Canaccord Genuity raised shares of Endologix from a “hold” rating to a “buy” rating and set a $15.50 price target on the stock in a research report on Monday, June 13th. Guggenheim assumed coverage on Endologix in a research report on Wednesday, June 8th. They issued a “buy” rating and a $16.00 target price on the stock. BTIG Research reissued a “buy” rating and issued a $16.00 target price on shares of Endologix in a research report on Wednesday, August 3rd. BMO Capital Markets reissued a “buy” rating and issued a $15.00 target price on shares of Endologix in a research report on Wednesday, August 3rd. Finally, Leerink Swann set a $13.00 target price on Endologix and gave the company a “hold” rating in a research report on Saturday, September 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $13.79.
Shares of Endologix (NASDAQ:ELGX) traded up 1.81% during mid-day trading on Tuesday, reaching $12.96. The company’s stock had a trading volume of 237,908 shares. The stock has a 50 day moving average of $12.23 and a 200-day moving average of $11.75. Endologix has a one year low of $6.51 and a one year high of $14.50. The stock’s market cap is $1.07 billion.
Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. The firm had revenue of $51 million for the quarter, compared to analyst estimates of $46.30 million. Endologix had a negative net margin of 82.39% and a negative return on equity of 41.88%. The business’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.18) EPS. On average, equities research analysts expect that Endologix will post ($0.74) EPS for the current fiscal year.
In related news, insider Michael V. Chobotov sold 14,000 shares of the business’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of $12.40, for a total transaction of $173,600.00. Following the completion of the transaction, the insider now owns 189,269 shares in the company, valued at $2,346,935.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Jose A. Lima sold 4,710 shares of the business’s stock in a transaction on Friday, August 19th. The stock was sold at an average price of $11.68, for a total transaction of $55,012.80. Following the transaction, the vice president now owns 42,594 shares of the company’s stock, valued at approximately $497,497.92. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.
Several institutional investors have recently modified their holdings of ELGX. Nomura Holdings Inc. bought a new position in Endologix during the second quarter valued at about $128,000. Teacher Retirement System of Texas increased its position in Endologix by 15.8% in the second quarter. Teacher Retirement System of Texas now owns 10,333 shares of the company’s stock valued at $129,000 after buying an additional 1,407 shares in the last quarter. OLD National Bancorp IN bought a new position in Endologix during the second quarter valued at about $129,000. Villere ST Denis J & Co. LLC bought a new position in Endologix during the second quarter valued at about $134,000. Finally, Legal & General Group Plc increased its position in Endologix by 34.9% in the first quarter. Legal & General Group Plc now owns 12,570 shares of the company’s stock valued at $106,000 after buying an additional 3,252 shares in the last quarter.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.